Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.
BACKGROUND
Anticoagulants and antiplatelet drugs (e.g., warfarin, clopidogrel and acetylsalicylic acid) are key therapeutic agents in the treatment of cardiovascular diseases. However, drug-drug interactions may lead to a greatly increased risk of gastrointestinal bleeding when these drugs are combined. We assessed whether antithrombotic drug combinations increased the risk of such bleeding in a general practice population.


METHODS
We conducted a population-based, retrospective case-control study using records in the United Kingdom General Practice Research Database from 2000 through 2005. Cases were identified as patients over 18 years of age with a first-ever diagnosis of gastrointestinal bleeding. They were matched with controls by physician practice, patient age and index date (date of diagnosis of bleeding). All eligible patients had to have at least 3 years of follow-up data in the database. Drug exposure was considered to be any prescription issued in the 90 days before the index date.


RESULTS
There were 4028 cases with a diagnosis of gastrointestinal bleeding and 40 171 matched controls. The prescribing of acetylsalicylic acid with either clopidogrel (adjusted rate ratio [RR] 3.90, 95% confidence interval [CI] 2.78-5.47) or warfarin (adjusted RR 6.48, 95% CI 4.25-9.87) was associated with a greater risk of gastrointestinal bleeding than that observed with each drug alone. The same was true when a nonsteroidal anti-inflammatory drug was combined with either clopidogrel (adjusted RR 2.93, 95% CI 1.74-4.93) or warfarin (RR 4.60, 95% CI 2.77-7.64).


CONCLUSIONS
Drug combinations involving antiplatelets and anticoagulants are associated with a high risk of gastrointestinal bleeding beyond that associated with each drug used alone. Physicians should be aware of these risks to better assess their patients' therapeutic risk-benefit profiles.
Delaney
Joseph A
JA
Division of Clinical Epidemiology, McGill University Health Centre, Montréal, Que.
Opatrny
Lucie
L
Brophy
James M
JM
Suissa
Samy
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D000077144:Clopidogrel; D004347:Drug Interactions; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives; D014859:Warfarin / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
J Thromb Thrombolysis. 2006 Apr;21(2):191-8
16622617
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):309-15
16858720
BMJ. 2006 Oct 7;333(7571):726
16984924
Am J Epidemiol. 2006 Nov 1;164(9):881-9
17005625
CMAJ. 2006 Oct 24;175(9):1087-92
17060659
Arch Intern Med. 2007 Jan 22;167(2):117-24
17242311
CMAJ. 2006 May 23;174(11):1563-9
16670396
Thromb Haemost. 2005 Sep;94(3):537-43
16268469
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
11087881
Pharmacotherapy. 2003 May;23(5):686-9
12741446
Br J Gen Pract. 2003 Apr;53(489):312-4
12879832
Gut. 2003 Sep;52(9):1265-70
12912856
Thromb Haemost. 1992 Jul 6;68(1):1-6
1514166
Lancet. 1997 Oct 11;350(9084):1097-9
10213569
J Public Health Med. 1999 Sep;21(3):299-304
10528957
Arch Intern Med. 2005 Apr 11;165(7):784-9
15824298
Ann Intern Med. 2005 Aug 16;143(4):241-50
16103468